World's Best Scientists 2026 revealed!

D-Index & Metrics

Chemistry

D-Index
57
Citations
10105
World Ranking
11248
National Ranking
3061

David B. Volkin publication distribution in Chemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Chemistry in 2026. The highlighted bar marks where David B. Volkin sits on this spectrum.

61–80 publications: 66 scientists 81–100 publications: 302 scientists 101–120 publications: 623 scientists 121–140 publications: 918 scientists 141–160 publications: 1,218 scientists 161–180 publications: 1,350 scientists 181–200 publications: 1,344 scientists 201–220 publications: 1,281 scientists 221–240 publications: 1,216 scientists 241–260 publications: 1,100 scientists 261–280 publications: 979 scientists 281–300 publications: 939 scientists 301–320 publications: 764 scientists 321–340 publications: 643 scientists 341–360 publications: 628 scientists 361–380 publications: 522 scientists 381–400 publications: 459 scientists 401–420 publications: 397 scientists 421–440 publications: 327 scientists 441–460 publications: 270 scientists 461–480 publications: 265 scientists 481–500 publications: 252 scientists 501–520 publications: 201 scientists 521–540 publications: 185 scientists 541–560 publications: 148 scientists 561–580 publications: 148 scientists 581–600 publications: 132 scientists 601–620 publications: 114 scientists 621–640 publications: 104 scientists 641–660 publications: 91 scientists 661–680 publications: 92 scientists 681–700 publications: 73 scientists 701–720 publications: 57 scientists 721–740 publications: 54 scientists 741–760 publications: 67 scientists 761–780 publications: 45 scientists 781–800 publications: 46 scientists 801–820 publications: 39 scientists 821–840 publications: 32 scientists 841–860 publications: 36 scientists 861–880 publications: 29 scientists 881–900 publications: 26 scientists 901–920 publications: 24 scientists 921–940 publications: 14 scientists 941–960 publications: 23 scientists 961–980 publications: 28 scientists 981–1,000 publications: 15 scientists 1,001–1,020 publications: 29 scientists 1,021–1,040 publications: 12 scientists 1,041–1,060 publications: 19 scientists 1,061–1,080 publications: 12 scientists 1,081–1,100 publications: 6 scientists 1,101–1,120 publications: 8 scientists 1,121–1,140 publications: 12 scientists 1,141–1,160 publications: 5 scientists 1,161–1,180 publications: 6 scientists 1,181–1,200 publications: 14 scientists 1,201–1,220 publications: 7 scientists 1,221–1,240 publications: 2 scientists 1,241–1,260 publications: 6 scientists 1,261–1,280 publications: 4 scientists 1,281–1,294 publications: 6 scientists 1,295+ publications: 100 scientists
61 publications 1,295+

This scientist: 188 publications — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,295 publications or more.

David B. Volkin D-index placement in Chemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Chemistry scientists ranked by Research.com in 2026. The highlighted bar marks where David B. Volkin sits on this spectrum.

40–41 D-Index: 289 scientists 42–43 D-Index: 612 scientists 44–45 D-Index: 808 scientists 46–47 D-Index: 776 scientists 48–49 D-Index: 835 scientists 50–51 D-Index: 861 scientists 52–53 D-Index: 872 scientists 54–55 D-Index: 933 scientists 56–57 D-Index: 1,051 scientists 58–59 D-Index: 930 scientists 60–61 D-Index: 882 scientists 62–63 D-Index: 834 scientists 64–65 D-Index: 731 scientists 66–67 D-Index: 775 scientists 68–69 D-Index: 683 scientists 70–71 D-Index: 646 scientists 72–73 D-Index: 561 scientists 74–75 D-Index: 501 scientists 76–77 D-Index: 437 scientists 78–79 D-Index: 388 scientists 80–81 D-Index: 354 scientists 82–83 D-Index: 292 scientists 84–85 D-Index: 275 scientists 86–87 D-Index: 254 scientists 88–89 D-Index: 235 scientists 90–91 D-Index: 185 scientists 92–93 D-Index: 192 scientists 94–95 D-Index: 155 scientists 96–97 D-Index: 163 scientists 98–99 D-Index: 125 scientists 100–101 D-Index: 105 scientists 102–103 D-Index: 105 scientists 104–105 D-Index: 112 scientists 106–107 D-Index: 88 scientists 108–109 D-Index: 68 scientists 110–111 D-Index: 69 scientists 112–113 D-Index: 65 scientists 114–115 D-Index: 79 scientists 116–117 D-Index: 61 scientists 118–119 D-Index: 44 scientists 120–121 D-Index: 37 scientists 122–123 D-Index: 40 scientists 124–125 D-Index: 33 scientists 126–127 D-Index: 26 scientists 128–129 D-Index: 34 scientists 130–131 D-Index: 35 scientists 132–133 D-Index: 25 scientists 134–135 D-Index: 27 scientists 136–137 D-Index: 17 scientists 138–139 D-Index: 16 scientists 140–141 D-Index: 20 scientists 142–143 D-Index: 20 scientists 144–145 D-Index: 15 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 9 scientists 150–151 D-Index: 16 scientists 152–153 D-Index: 11 scientists 154–155 D-Index: 9 scientists 156–157 D-Index: 3 scientists 158 D-Index: 3 scientists 159+ D-Index: 98 scientists
40 D-Index 159+

This scientist: 57 D-Index — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 159 D-Index or more.

Overview

David B. Volkin is affiliated with the University of Kansas in the United States and has contributed extensively to research in medicine and biochemistry, genetics, and molecular biology. Their work spans multiple subfields including infectious diseases, molecular biology, animal science and zoology, cardiology and cardiovascular medicine, and epidemiology.

Their research focuses on a range of main topics, emphasizing viral gastroenteritis research and epidemiology, SARS-CoV-2 and COVID-19 research, protein purification and stability, animal virus infections studies, viral infections and immunology research, viral infectious diseases and gene expression in insects, and immunotherapy and immune responses.

Recent publications authored or co-authored by David B. Volkin include:

  • Addressing the Cold Reality of mRNA Vaccine Stability, 2020, Journal of Pharmaceutical Sciences
  • The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case, 2022, Journal of Pharmaceutical Sciences
  • Development of spirulina for the manufacture and oral delivery of protein therapeutics, 2022, Nature Biotechnology
  • Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice, 2021, Proceedings of the National Academy of Sciences
  • Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?, 2021, Journal of Pharmaceutical Sciences

Frequent co-authors collaborating with David B. Volkin include:

  • Sangeeta B. Joshi, with 50 joint publications
  • Ozan S. Kumru, with 29 joint publications
  • John M. Hickey, with 19 joint publications
  • Kawaljit Kaur, with 15 joint publications
  • J. Christopher Love, with 14 joint publications

The scientist's work appears predominantly in the following publication venues:

  • Journal of Pharmaceutical Sciences, 18 publications
  • bioRxiv (Cold Spring Harbor Laboratory), 9 publications
  • Human Vaccines & Immunotherapeutics, 6 publications
  • Vaccine, 5 publications
  • Vaccines, 4 publications

Best Publications

  • Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

    John W. Shiver;Tong-Ming Fu;Ling Chen;Danilo R. Casimiro

  • Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene

    Danilo R. Casimiro;Ling Chen;Tong-Ming Fu;Robert K. Evans

  • Protein–excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development

    Tim J. Kamerzell;Reza Esfandiary;Sangeeta B. Joshi;C. Russell Middaugh

  • Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.

    Ozan S. Kumru;Sangeeta B. Joshi;Dawn E. Smith;C. Russell Middaugh

  • Addressing the Cold Reality of mRNA Vaccine Stability.

    Daan J.A. Crommelin;Thomas J. Anchordoquy;David B. Volkin;Wim Jiskoot

  • Enzyme thermoinactivation in anhydrous organic solvents

    David B. Volkin;Andrea Staubli;Robert Langer;Alexander M. Klibanov

  • Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release

    Wim Jiskoot;Theodore W. Randolph;David B. Volkin;C. Russell Middaugh

  • Nature of the interaction of heparin with acidic fibroblast growth factor

    Henryk Mach;David B. Volkin;Carl J. Burke;C. Russell Middaugh

  • Development of stable liquid formulations for adenovirus-based vaccines.

    Robert K. Evans;Denise K. Nawrocki;Lynne A. Isopi;Donna M. Williams

  • Nature of the interaction of growth factors with suramin.

    C. Russell Middaugh;Henryk Mach;Carl J. Burke;David B. Volkin

  • Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form.

    Pei Qi;David B. Volkin;Hui Zhao;Michael L. Nedved

  • Physical stabilization of acidic fibroblast growth factor by polyanions.

    D.B. Volkin;P.K. Tsai;J.M. Dabora;J.O. Gress

  • Thermal destruction processes in proteins involving cystine residues.

    Unknown

  • High-Throughput Biophysical Analysis of Protein Therapeutics to Examine Interrelationships Between Aggregate Formation and Conformational Stability

    Rajoshi Chaudhuri;Rajoshi Chaudhuri;Yuan Cheng;C. Russell Middaugh;David B. Volkin

  • Development of spirulina for the manufacture and oral delivery of protein therapeutics

    Unknown

  • Ultraviolet Absorption Spectroscopy

    H Mach;D B Volkin;C J Burke;C R Middaugh

  • Structural Characterization of IgG1 mAb Aggregates and Particles Generated under Various Stress Conditions

    Srivalli Telikepalli;Ozan S. Kumru;Cavan Kumar Kalonia;Reza Esfandiary

  • Stabilization of human papillomavirus virus-like particles by non-ionic surfactants.

    Unknown

  • Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies.

    Unknown

  • Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation

    Klaus Wuchner;Jochen Büchler;Rene Spycher;Paul Dalmonte

  • Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody.

    Ranajoy Majumdar;Prakash Manikwar;John M. Hickey;Hardeep S. Samra

  • Degradative covalent reactions important to protein stability

    Unknown

  • Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility During Formulation Development with IgG1 Monoclonal Antibodies

    Todd J. Gibson;Katie Mccarty;Iain J. McFadyen;Ethan Cash

  • Vaccine-Induced Immunity in Baboons by Using DNA and Replication-Incompetent Adenovirus Type 5 Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

    Danilo R. Casimiro;Aimin Tang;Ling Chen;Tong-Ming Fu

  • Compatibility, Physical Stability, and Characterization of an IgG4 Monoclonal Antibody After Dilution into Different Intravenous Administration Bags

    Ozan S. Kumru;Jun Liu;Junyan A. Ji;Wilson Cheng

  • A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.

    Neal Whitaker;Jian Xiong;Samantha E. Pace;Vineet Kumar

  • Formulation and stabilization of recombinant protein based virus-like particle vaccines.

    Nishant K. Jain;Neha Sahni;Ozan S. Kumru;Sangeeta B. Joshi

Frequent Co-Authors

C. Russell Middaugh
C. Russell Middaugh University of Kansas
Nicholas J. Mantis
Nicholas J. Mantis New York State Department of Health
Christian Schöneich
Christian Schöneich University of Kansas
Wim Jiskoot
Wim Jiskoot Leiden University
Daan J.A. Crommelin
Daan J.A. Crommelin Utrecht University
Dan H. Barouch
Dan H. Barouch Harvard Medical School
Gerhard Winter
Gerhard Winter Ludwig-Maximilians-Universität München
John F. Carpenter
John F. Carpenter University of Colorado Anschutz Medical Campus
Stanley J. Cryz
Stanley J. Cryz University of Massachusetts Chan Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Chemistry in the USA opens doors to a variety of rewarding careers beyond the traditional lab environment. For those interested in healthcare, understanding whether is it hard to become a pharmacist can help set expectations for rigorous education and training required in that field.

If your interest leans toward forensic science, there are numerous specialized roles such as a forensic autopsy technician, which combines chemistry knowledge with investigative science. Many students opt to pursue a forensic degree online to gain flexible access to accredited programs that fit their schedules.

For those interested in the psychological aspects of crime, forensic psychology master's programs online offer a pathway to advanced study that complements a chemistry background with behavioral science insights.

Exploring these interdisciplinary online degrees can enhance your skill set and expand your career options in dynamic, in-demand fields that build on a chemistry foundation.

Best Scientists Citing David B. Volkin

Trending Scientists

Recently Published Articles